Mint Sirisawad

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

Life Sciences, Immunology, Pharmacology +17

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Sriram Balasubramanian, Jason Ramos, Weigang Luo et al. · Leukemia · 2008 · 446 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

Shanthi Adimoolam, Mint Sirisawad, Jun Chen et al. · Proceedings of the National Academy of Sciences · 2007 · 235 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

Savita Bhalla, Sriram Balasubramanian, Kevin A. David et al. · Clinical Cancer Research · 2009 · 98 citations · Full text

Life Sciences, Oncology, Pharmacology +17

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose et al. · Clinical Cancer Research · 2015 · 94 citations

Medicine, Pharmacology, Pharmacotherapy +14